MedTrace Logo

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

NCT00002634 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2013-07-03

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy, radiation therapy, immunotherapy, and bone marrow transplantation in treating patients with neuroblastoma.

Conditions

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

monoclonal antibody 3F8

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

mesna

DRUG

perfosfamide

DRUG

vincristine sulfate

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

in vitro-treated bone marrow transplantation

RADIATION

low-LET cobalt-60 gamma ray therapy

RADIATION

low-LET photon therapy

RADIATION

radioisotope therapy

Sponsors & Collaborators

Principal Investigators

  • Nai-Kong V. Cheung, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-02-28
Primary Completion
2004-09-30
Completion
2004-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002634 on ClinicalTrials.gov